Table 2.

Subgroup analyses of changes in sleep onset latency recorded with the electronic sleep diary

Subgroups	Phases	Changesa			Wilcoxon’s signed rank sum test
		n	Mean ± SD	95% CI	P value
Autism spectrum disorder
Absent	Screening phase	–	–	–	–
	Medication phase I	25	−36.2 ± 40.5	−53.0 to −19.5	<  0.0001
Present	Screening phase	–	–	–	–
	Medication phase I	74	−36.8 ± 48.1	−48.0 to −25.7	<  0.0001
ADHD
Absent	Screening phase	–	–	–	–
	Medication phase I	39	−42.7 ± 62.5	−62.9 to −22.4	< 0.0001
Present	Screening phase	–	–	–	–
	Medication phase I	60	−32.8 ± 31.2	−40.9 to −24.7	< 0.0001
Intellectual disabilities
Absent	Screening phase	–	–	–	–
	Medication phase I	77	−35.8 ± 44.6	−46.0 to −25.7	< 0.0001
Present	Screening phase	–	–	–	–
	Medication phase I	22	−39.7 ± 52.1	−62.8 to −16.6	< 0.0001
Motor disorders
Absent	Screening phase	–	–	–	–
	Medication phase I	90	−37.4 ± 47.9	−47.4 to −27.3	< 0.0001
Present	Screening phase	–
	Medication phase I	9	−29.8 ± 19.7	−45.0 to −14.6	0.0039
Specific learning disorder
Absent	Screening phase	–	–	–	–
	Medication phase I	93	−36.0 ± 47.1	−45.7 to −26.3	< 0.0001
Present	Screening phase	–	–	–	–
	Medication phase I	6	−46.8 ± 25.3	−73.4 to −20.3	0.0313

^a: Change = (median during the last 7 days of the medication phase I) - (median during the last 7 days of the screening phase)

SD Standard deviation, CI Confidence interval, ADHD Attention-deficit/hyperactivity disorder